AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17684047
Drug: Standard replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard replacement therapy for adrenal insufficiency
Trial: 17686450
Drug: One-drug group
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-drug group (prostaglandin analogs)
Trial: 17686450
Drug: Two-drug group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-drug group (prostaglandin analogs plus adjunctive medication)
Trial: 17686450
Drug: Beta-adrenoceptor antagonists
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-adrenoceptor antagonists (part of two-drug group)
Trial: 17687130
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m²) administered as four weekly infusions
Trial: 17694552
Drug: Darbepoetin-alpha at
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin-alpha at a dose of 200 microg every 2 weeks
Trial: 17700015
Drug: CVVH without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CVVH without regional citrate anticoagulation (anticoagulant-free predilution CVVH)
Trial: 17707182
Drug: Discharge use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discharge use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker or beta-blocker
Trial: 17709602
Drug: Imatinib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib (400 mg daily) dose de-escalation
Trial: 17709602
Drug: Reinitiation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinitiation of therapy at prior effective dose
Trial: 17709602
Drug: Imatinib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib (300 to 400 mg daily)
Trial: 17709827
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus chemotherapy (cycles 2-7)
Trial: 17717136
Drug: Valproate (VPA),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valproate (VPA), a histone deacetylase inhibitor, used as a chronic treatment for epileptic disorders.
Trial: 17717285
Drug: Flexible intensive
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible intensive insulin therapy
Trial: 17723147
Drug: ORAL IMPACT
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ORAL IMPACT (immunonutrient formula)
Trial: 17725843
Drug: Duloxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (60 mg once a day for 12 weeks)
Trial: 17761590
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy (previously received)
Trial: 17761710
Drug: Hydralazine (182
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine (182 mg for rapid acetylators, 83 mg for slow acetylators) and magnesium valproate (40 mg/kg) added to chemotherapy schedule.
Trial: 17761710
Drug: Chemotherapy (cisplatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (cisplatin, carboplatin, paclitaxel, vinorelbine, gemcitabine, pemetrexed, topotecan, doxorubicin, cyclophosphamide, anastrozole).
Trial: 17767471
Drug: Lansoprazole treatment
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole treatment for 5 years (median)
Trial: 17822557
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with HER2 ICD protein-containing dendritic cells (DC) administered intradermally/subcutaneously four times at 3 week intervals.
Trial: 17846226
Drug: pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegylated liposomal doxorubicin (20 mg/m(2)) plus interleukin-12 (IL-12; 300 ng/kg subcutaneously twice weekly) followed by 500 ng/kg subcutaneous IL-12 twice weekly for up to 3 years
Trial: 17869664
Drug: Estimated brachytherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estimated brachytherapy dose to APA
Trial: 17875804
Drug: Combined vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined vaccine of PR1 and WT1 peptides in Montanide adjuvant with granulocyte-macrophage colony-stimulating factor
Trial: 17875804
Drug: Combined vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined vaccine of PR1 and WT1 peptides
Trial: 17876370
Drug: Topical acetylcholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical acetylcholine chloride
Trial: 17893227
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral lenalidomide daily
Trial: 17893227
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg lenalidomide on days 1 to 21 of a 28-day cycle
Trial: 17893227
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg lenalidomide
Trial: 17897470
Drug: Active nitric
RxNorm normalized name: Nitric Acid
DrugBank: Nitric acid (DB15995)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active nitric oxide releasing patches
Trial: 21831297
Drug: Transdermal rotigotine
RxNorm normalized name: rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal rotigotine patch
Trial: 17910637
Drug: UCB graft
RxNorm normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UCB graft with CD34(+) cell dose
Trial: 17910637
Drug: UCB graft
RxNorm normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UCB graft with CD3(+) cell dose
Trial: 17910637
Drug: UCB graft
RxNorm normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UCB graft with higher cell doses of CD34(+), committed CD34(+) progenitors and CD3(+) T cells
Trial: 17915028
Drug: Electronic prescribing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic prescribing software with decision support at the point of care; details on dosage and duration not applicable as it is a software intervention.
Trial: 17915977
Drug: Lamotrigine (dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine (dosing ranged from 25 mg every other day to 300 mg/day)
Trial: 17916243
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment with moxifloxacin followed by delayed elective cholecystectomy
Trial: 17923600
Drug: Lower serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower serum sodium concentration (per 5-mEq/L increment)
Trial: 17923600
Drug: Higher serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher serum urea nitrogen concentration (per 10-mg/dL increment)
Trial: 17923600
Drug: Absence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absence of lipid-lowering drug therapy
Trial: 17934551
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg q.d. for 7 weeks
Trial: 17934748
Drug: Low-dose mitomycin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose mitomycin C (0.01 nM) for 2 weeks followed by 0.1 to 100 microM mitomycin C; P-glycoprotein expression analysis using flow cytometry, immunoblotting, and RT-PCR.
Trial: 17934748
Drug: Low-dose mitomycin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose mitomycin C (0.01 nM) with verapamil (4 microM); P-glycoprotein expression analysis.
Trial: 17936715
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (vitrectomy, intravitreal triamcinolone acetonide injection, and macular laser photocoagulation)
Trial: 17951527
Drug: Deferasirox at
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox at 20 mg/kg per day
Trial: 17951527
Drug: Deferasirox at
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox at 30 mg/kg per day
Trial: 17954810
Drug: homocysteine level
RxNorm normalized name: mecysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: homocysteine level lowering therapy
Trial: 17959855
Drug: Arsenic trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Arsenic trioxide (ATO) at 0.15 mg/kg per day
Trial: 17959855
Drug: Arsenic trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Arsenic trioxide (ATO) at 0.2 mg/kg per day
Trial: 17975162
Drug: Defucosylated anti-CCR4
RxNorm normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Defucosylated anti-CCR4 monoclonal antibody KM2760
Trial: 17975162
Drug: Defucosylated anti-CCR4
RxNorm normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Defucosylated anti-CCR4 monoclonal antibody KM2760 combined with immunomodulatory cytokines (interleukin-12, IFN-alpha-2b, IFN-gamma)
Trial: 17981652
Drug: Nelfinavir monotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nelfinavir monotherapy, 1250 mg orally, BID for 3 weeks
Trial: 17984237
Drug: Octreotide-LAR 20
RxNorm normalized name: octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Octreotide-LAR 20 mg/q28d
Trial: 17984237
Drug: Octreotide-LAR 30
RxNorm normalized name: octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Octreotide-LAR 30 mg/q28d
Trial: 17984237
Drug: Octreotide-LAR 40
RxNorm normalized name: octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Octreotide-LAR 40 mg/q28d
Trial: 17989313
Drug: BiRD (Biaxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BiRD (Biaxin [clarithromycin] 500 mg orally twice daily, lenalidomide [Revlimid] 25 mg orally daily on days 1 to 21, dexamethasone 40 mg orally once weekly)
Trial: 17996820
Drug: Beta-blockers at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers at hospital discharge
Trial: 17996820
Drug: No beta-blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No beta-blockers at hospital discharge
Trial: 17999759
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly dosing of epoetin delta
Trial: 17999759
Drug: Once weekly
RxNorm normalized name: Actonel 35 4-Week Once Weekly Dosepack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly dosing of epoetin delta
Trial: 18003886
Drug: Ofatumumab 100
RxNorm normalized name: ofatumumab 100 MG in 5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofatumumab 100 mg (1 dose) + 500 mg (3 doses)
Trial: 18003886
Drug: Ofatumumab 300
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ofatumumab 300 mg (1 dose) + 1000 mg (3 doses)
Trial: 18003886
Drug: Ofatumumab 500
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ofatumumab 500 mg (1 dose) + 2000 mg (3 doses)
Trial: 18005455
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBOT) at 1.5 atm and 100% oxygen
Trial: 18005455
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBOT) at 1.3 atm and 24% oxygen
Trial: 18021496
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR (300 mg on day 1, 600 mg on day 2, 400-800 mg from day 4 to 84)
Trial: 18024436
Drug: Low-dose CT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT screening interpretation by 16 radiologists
Trial: 18025537
Drug: Trandolapril therapy
RxNorm normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trandolapril therapy
Trial: 18026714
Drug: Oral taurine
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral taurine (TAU)
Trial: 18026714
Drug: Intralipid and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid and heparin (IH) infusion
Trial: 18042798
Drug: Etanercept plus
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept plus steroids
Trial: 18042798
Drug: Etanercept plus
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept plus steroids (related donors)
Trial: 18042798
Drug: Steroids alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids alone (related donors)
Trial: 18042798
Drug: Etanercept plus
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept plus steroids (unrelated donors)
Trial: 18042798
Drug: Steroids alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids alone (unrelated donors)
Trial: 21098399
Drug: Nilotinib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilotinib (400 mg twice daily)
Trial: 18053191
Drug: Bortezomib in
RxNorm normalized name: bortezomib Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib in combination with celecoxib (escalating doses of bortezomib on a weekly or twice-weekly schedule and celecoxib 200 mg to 400 mg twice daily)
Trial: 18053199
Drug: Chlamydia screening
RxNorm normalized name: Chlamydia trachomatis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlamydia screening and treatment for those found to be infected
Trial: 18054887
Drug: Intravenous bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous bevacizumab (5 mg/kg)
Trial: 18055730
Drug: Spinal analgesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal analgesia (7.5 mg bupivacaine)
Trial: 18055865
Drug: Eculizumab (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab (600 mg every 7 +/- 2 days for 4 weeks; 900 mg 7 +/- 2 days later; followed by 900 mg every 14 +/- 2 days for a total treatment period of 52 weeks)
Trial: 18056840
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of multilineage dysplasia (MLD) in 1332 individuals receiving intensive AML therapy
Trial: 18070995
Drug: Placebo-based antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-based antihypertensive therapy
Trial: 18071030
Drug: Intramuscular interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular interferon beta-1a plus oral doxycycline (100 mg daily for 4 months)
Trial: 18071034
Drug: Pergolide treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pergolide treatment (meta-analysis)
Trial: 18078870
Drug: Plant sterols
RxNorm normalized name: Plant Sterols/Stanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterols (1.0 g/1000 kcal)
Trial: 18079362
Drug: SGN-30 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGN-30 (4 dose levels: 2, 4, 8, or 12 mg/kg)
Trial: 18079362
Drug: SGN-30 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGN-30 (6 weekly doses)
Trial: 18082486
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clopidogrel and acetylsalicylic acid
Trial: 18084623
Drug: IV bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV bolus injection of ferumoxytol (carboxymethyl dextran-based magnetic nanoparticle)
Trial: 18089335
Drug: Caspofungin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin (50 to 100 mg/day) for invasive candidiasis (IC)
Trial: 18089335
Drug: Caspofungin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin (50 to 100 mg/day) for invasive aspergillosis (IA)
Trial: 18089335
Drug: Caspofungin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin (50 to 100 mg/day)
Trial: 18090358
Drug: Estradiol level
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol level of 100 pg/mL
Trial: 18090508
Drug: Escitalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (20 mg/day for 3 weeks after a 1-week titration at 10 mg/day, then increased to a maximum of 50 mg/day for 12 weeks if needed)
Trial: 18090508
Drug: Escitalopram (high-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (high-dose, mean dose 33.8 mg/day at endpoint)
Trial: 18096059
Drug: Vinorelbine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine (20 mg/m2) and topotecan (escalating doses of 2, 2.5, 3, 3.5, and 4 mg/m2) administered on days 1 and 8 every 21 days
Trial: 18163506
Drug: Intravenous immunoglobulins
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulins (IVIGs) administered at 0.5 gm/kg/day for 4 days, as additional therapy administered monthly for 6 months.
Trial: 18166563
Drug: Methadone maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone maintenance (50-105 mg/day)
Trial: 18174826
Drug: Stimulant medication
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant medication (implied as a comparison)
Trial: 18178411
Drug: Low hemoglobin
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low hemoglobin (<12.1 g/dl)
Trial: 18178412
Drug: BNP >or=840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNP >or=840 pg/ml and Tn increased
Trial: 18178412
Drug: BNP <840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNP <840 pg/ml and Tn not increased
Trial: 18182574
Drug: Cytarabine (0.5-1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytarabine (0.5-1.5 mg/kg)
Trial: 18182574
Drug: ML-DS with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ML-DS with history of TL
Trial: 18182574
Drug: ML-DS without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ML-DS without documented TL
Trial: 18184959
Drug: Sirolimus therapy
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus therapy for 12 months
Trial: 18184959
Drug: Sirolimus therapy
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus therapy for 12 months (in patients with lymphangioleiomyomatosis)
Trial: 18184959
Drug: 1 year
RxNorm normalized name: COVID vacc 2024-2025 (5-11 years) (Pfizer)/PF 10 mcg/0.3 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 year after sirolimus therapy was discontinued
Trial: 18190252
Drug: WNV DNA
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WNV DNA vaccine (3 doses)
Trial: 18191528
Drug: Preoperative chemoradiation
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemoradiation therapy (CRT) followed by resection
Trial: 18206507
Drug: Rituximab (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (1000 mg, 2 intravenous applications, 2 weeks apart)
Trial: 18206856
Drug: Triiodothyronine (T3)
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triiodothyronine (T3) augmentation treatment for 4 weeks
Trial: 18206856
Drug: Normal control
RxNorm normalized name: Precision, Normal Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal control subjects (no treatment)
Trial: 18212631
Drug: Sirolimus (SIR)
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus (SIR) monotherapy
Trial: 18212631
Drug: Sirolimus plus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus plus Tacrolimus (SIR-TAC) combination therapy
Trial: 18221542
Drug: DC/Apo-Nec vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DC/Apo-Nec vaccine (dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells)
Trial: 18221542
Drug: DC/Apo-Nec vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DC/Apo-Nec vaccine